Recovery

What Is TB-500?

TB-500 is a synthetic peptide associated with thymosin beta-4 research, used in cell-migration and actin-regulation models.

Disclaimer: Information is for research and educational purposes only. Catalog materials are not approved for human or veterinary use.

TB-500 is the catalog name most researchers use for a synthetic peptide associated with thymosin beta-4. Thymosin beta-4 is a naturally occurring peptide involved in actin binding. The synthetic material is used in laboratory models of cell migration, cytoskeletal organization, and tissue-response signaling.

Zeptix Labs lists TB-500 (Thymosin Beta-4) as a research-use-only peptide. It is not sold for therapeutic, cosmetic, or veterinary application.

TB-500 and thymosin beta-4

The literature often treats TB-500 as a practical name for a thymosin beta-4 related sequence used in experimental work. When you cite a paper, match the exact sequence and fragment discussed in that paper to the lot you are using. Names in storefronts are shorter than names in methods sections.

Common research frames

  • Cell-migration and actin-regulation models.
  • Angiogenesis and vascular-signaling readouts.
  • Muscle- and tendon-remodeling pathway work.

Catalog neighbors

BPC-157 is the usual comparison peptide in recovery-themed catalogs. Zeptix also lists a BPC-157 / TB-500 blend, plus GLOW and KLOW, which include TB-500 among other components. Use the single TB-500 SKU when the protocol needs that variable alone.

TB-500 from Zeptix Labs is for laboratory research only and is not intended for human or veterinary use.

Research context and evidence base

TB-500 discussions frequently draw from thymosin beta-4 research on actin sequestration, cell migration, angiogenesis, and tissue remodeling. The catalog name and the molecule described in a paper are not automatically interchangeable. Researchers should verify the sequence or fragment, assay system, and identity data before treating a publication as applicable to a specific vial.12

How to interpret the published evidence

Evidence should be sorted by study type before it is summarized. Analytical characterization establishes what material was tested; cell work can suggest pathways; animal models can explore integrated biology; and human studies, when they exist, apply only to their regulated product, population, and design. One layer should not be presented as if it proves the next.3

Experimental design questions

In TB-500 or thymosin beta-4 models, verify whether the paper used the full sequence, a fragment, or an endogenous protein preparation. Migration assays need consistent confluence and imaging intervals, while actin-related work needs an appropriate cytoskeletal readout. A BPC-157 comparison or multi-peptide blend requires additional single-compound controls if attribution to one component matters.

Building a reproducible laboratory record

For work involving What Is TB-500, record the supplier, SKU, lot number, labeled amount, receipt date, storage history, reconstitution conditions, concentration calculation, control material, instrument or assay version, and prespecified endpoint. Keep the matching certificate of analysis with the run record. These details make a result auditable and help distinguish biological variation from a handling or identity problem.

  • Match the exact compound, sequence, modification, and formulation to the cited methods.
  • Use positive, negative, and vehicle controls appropriate to the assay.
  • Define concentrations, time points, exclusions, and endpoints before reviewing results.
  • Report null and unexpected findings alongside the planned readouts.

Quality, limitations, and research-use status

A certificate of analysis supports lot traceability but does not establish a biological outcome. Investigators remain responsible for method suitability, independent confirmation when required, and compliance with institutional rules. Zeptix Labs materials are supplied for qualified laboratory research only and are not drugs, supplements, cosmetics, foods, or materials for human or veterinary administration.

Reporting results without overreach

When reporting What Is TB-500, state what the experiment directly measured and keep interpretation within that boundary. Include model limitations, uncertainty, failed quality controls, and alternative explanations. Avoid turning preclinical observations into treatment language or assuming that a statistically significant marker change is biologically important. Clear limitations make the article more useful to researchers and prevent laboratory evidence from being mistaken for consumer guidance.

References

  1. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin β4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261–1270. https://doi.org/10.1083/jcb.119.5.1261 https://doi.org/10.3390/ph18020185
  2. Sosne G, Wheeler LA, Zijah SS, et al. Thymosin β4: a novel corneal wound-healing and anti-inflammatory agent. Ann N Y Acad Sci. 2007;1112:232–240. https://pubmed.ncbi.nlm.nih.gov/17947584/ https://pubmed.ncbi.nlm.nih.gov/23755725/
  3. Smartt JM, Watkins SC, Zaidi HA, et al. A Phase 2 trial of topical Thymosin β4 (RGN-137) for chronic pressure and venous stasis ulcers. Wound Repair Regen. 2007;15(4):544–552. https://pubmed.ncbi.nlm.nih.gov/17650097/
  4. Ti D, Hao H, Fu X, et al. Thymosin β4 promotes tendon healing by improving collagen organization and mechanical strength. J Orthop Res. 2010;28(5):673–681. https://pubmed.ncbi.nlm.nih.gov/19902491/ https://pubmed.ncbi.nlm.nih.gov/8298609/
  5. Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and repair. J Biol Chem. 2010;285(51):39345–39354. https://pubmed.ncbi.nlm.nih.gov/20691219/
  6. Stewart DJ, Wei CC, Pabon M, et al. Thymosin β4 confers long-term survival benefit in a murine model of acute myocardial infarction. Circ Res. 2012;111(7):940–950. https://doi.org/10.1161/CIRCRESAHA.112.268680
  7. Fan J, Xu G, Jiang T, et al. Anti-fibrotic and anti-inflammatory effects of Thymosin β4 in organ injury models. Front Endocrinol (Lausanne). 2021;12:767785. https://www.frontiersin.org/articles/10.3389/fendo.2021.767785/full
  8. Yang Y, Chen X, Hu Y, et al. Thymosin β4 reduces renal fibrosis and protects kidney function in models of injury. Nephrol Dial Transplant. 2013;28(6):1620–1628. https://pubmed.ncbi.nlm.nih.gov/23427353/
  9. Sosne G, Darby MG, Tien DW, Wheeler LA, McCabe LA, Kleinman HK. Thymosin β4 promotes corneal epithelial migration and healing. Expert Opin Biol Ther. 2014;14(2):271–279. https://pubmed.ncbi.nlm.nih.gov/24354866/
  10. Philp D, St-Surin S, Cha HJ, et al. Thymosin β4 induces hair growth via stem-cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95–103. https://pubmed.ncbi.nlm.nih.gov/17947589/
Catalog

Related products

Continue reading

Related articles